Clinical Development Failure: The company's product candidates are in various stages of development, and there is no guarantee that they will successfully complete clinical trials or demonstrate sufficient efficacy and safety for approval.

Regulatory Approval Uncertainty: Even if clinical trials are successful, obtaining regulatory approval from agencies like the FDA is a complex and lengthy process with no assurance of success.

Future Capital Requirements: Developing new drugs is highly capital-intensive, and the company will likely need to raise substantial additional capital, which may lead to significant shareholder dilution or inability to fund operations.